Global Eye Cancer Treatment Market
Global Eye Cancer Treatment Market

Eye Cancer Treatment Comprehensive Study by Type (Eyelid Tumor, Corneal Tumor, Uveal Melanoma, Orbital Tumor), Treatment (Surgery, Radiation Therapy, Laser Therapy, Chemotherapy, Others), End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Others) Players and Region - Global Market Outlook to 2027

Eye Cancer Treatment Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 220 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Eye Cancer Treatment?
Eye cancer often called ocular cancer, affects both children and adults. It manifests as growth that begins in and around the eye. Eye cancer can be divided into two categories. The first signs of primary intraocular malignancy appear in the eyeballs. The most prevalent kind is primary intraocular melanoma, which is followed by primary intraocular lymphoma. Retinoblastoma is a type of primary intraocular malignancy that primarily affects youngsters. Secondary intraocular cancer is a metastatic malignancy that has spread to the eyes from other regions of the body. Secondary intraocular cancer is more common than initial intraocular cancer, and it is frequently the result of metastatic breast and lung tumors.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledNovartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (United States), GlaxoSmithKline plc (United Kingdom), Bayer AG (Germany), Amgen Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland) and Janssen Global Services, LLC (United States)
CAGR%


The market study is broken down by Type (Eyelid Tumor, Corneal Tumor, Uveal Melanoma and Orbital Tumor) and major geographies with country level break-up.

Some of the corporations' favorite market-exploration techniques include mergers and acquisitions, expansions, investments, new service launches, and collaborations. The company is giving its fair share of the company's expansion. The major key players like Novartis AG, Spectrum Pharmaceuticals Inc., GlaxoSmithKline plc, and Bayer AG are contributing their share for increasing the market growth. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (United States), GlaxoSmithKline plc (United Kingdom), Bayer AG (Germany), Amgen Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland) and Janssen Global Services, LLC (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sanofi (France), AbbVie Inc. (United States), Pfizer Inc. (United States), Merck & Co. Inc. (United States), Bristol-Myers Squibb Company (United States) and OncoMed Pharmaceuticals (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Eye Cancer Treatment market by Type, Application and Region.

On the basis of geography, the market of Eye Cancer Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Eye Cancer Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Eye Cancer Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In May 2021, The US Food and Drug Administration (FDA) has approved Amgen's LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally progressed or metastatic non-small cell lung cancer (NSCLC).


Market Trend
  • Increasing Number of Targeted and Innovative Therapies
  • Advancements in the Medical Science

Market Drivers
  • Rise In Prevalence of Eye Cancers and Increasing Geriatric Population across the Globe
  • Rising Healthcare Expenditures and Innovations in Healthcare Facilities Are Likely To Boost Market Expansion during the Forecast Period
  • Existence of a Solid Pipeline of Drug Therapies, New Product Launches, and Considerable R&D Activities for Developing Occular Cancer Therapeutics

Opportunities
  • Increasing Drug manufactures in the developing country
  • Increasing R & D Department on the Appendix Cancer Treatment

Restraints
  • High Cost of Treatment
  • Some Times Chances of Side Effects of Medicines

Challenges
  • Strict Government Rules
  • Lack of Awareness of Targeted Therapy Treatment in Rural Areas


Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (United States), GlaxoSmithKline plc (United Kingdom), Bayer AG (Germany), Amgen Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland) and Janssen Global Services, LLC (United States) etc.

2. Can we have customized study for Eye Cancer Treatment Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Eye Cancer Treatment Market by 2027?
Analysts at AMA estimates Eye Cancer Treatment Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Type
  • Eyelid Tumor
  • Corneal Tumor
  • Uveal Melanoma
  • Orbital Tumor
By Treatment
  • Surgery
  • Radiation Therapy
  • Laser Therapy
  • Chemotherapy
  • Others

By End-User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise In Prevalence of Eye Cancers and Increasing Geriatric Population across the Globe
      • 3.2.2. Rising Healthcare Expenditures and Innovations in Healthcare Facilities Are Likely To Boost Market Expansion during the Forecast Period
      • 3.2.3. Existence of a Solid Pipeline of Drug Therapies, New Product Launches, and Considerable R&D Activities for Developing Occular Cancer Therapeutics
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Rules
      • 3.3.2. Lack of Awareness of Targeted Therapy Treatment in Rural Areas
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Targeted and Innovative Therapies
      • 3.4.2. Advancements in the Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Eye Cancer Treatment, by Type, Treatment, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Eye Cancer Treatment (Value)
      • 5.2.1. Global Eye Cancer Treatment by: Type (Value)
        • 5.2.1.1. Eyelid Tumor
        • 5.2.1.2. Corneal Tumor
        • 5.2.1.3. Uveal Melanoma
        • 5.2.1.4. Orbital Tumor
      • 5.2.2. Global Eye Cancer Treatment by: End-User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Eye Cancer Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Eye Cancer Treatment (Price)
      • 5.3.1. Global Eye Cancer Treatment by: Type (Price)
  • 6. Eye Cancer Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Spectrum Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda Pharmaceuticals Company Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Janssen Global Services, LLC (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Eye Cancer Treatment Sale, by Type, Treatment, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Eye Cancer Treatment (Value)
      • 7.2.1. Global Eye Cancer Treatment by: Type (Value)
        • 7.2.1.1. Eyelid Tumor
        • 7.2.1.2. Corneal Tumor
        • 7.2.1.3. Uveal Melanoma
        • 7.2.1.4. Orbital Tumor
      • 7.2.2. Global Eye Cancer Treatment by: End-User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Eye Cancer Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Eye Cancer Treatment (Price)
      • 7.3.1. Global Eye Cancer Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Eye Cancer Treatment: by Type(USD Million)
  • Table 2. Eye Cancer Treatment Eyelid Tumor , by Region USD Million (2016-2021)
  • Table 3. Eye Cancer Treatment Corneal Tumor , by Region USD Million (2016-2021)
  • Table 4. Eye Cancer Treatment Uveal Melanoma , by Region USD Million (2016-2021)
  • Table 5. Eye Cancer Treatment Orbital Tumor , by Region USD Million (2016-2021)
  • Table 6. Eye Cancer Treatment: by End-User(USD Million)
  • Table 7. Eye Cancer Treatment Hospitals , by Region USD Million (2016-2021)
  • Table 8. Eye Cancer Treatment Clinics , by Region USD Million (2016-2021)
  • Table 9. Eye Cancer Treatment Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 10. Eye Cancer Treatment Others , by Region USD Million (2016-2021)
  • Table 11. South America Eye Cancer Treatment, by Country USD Million (2016-2021)
  • Table 12. South America Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 13. South America Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 14. South America Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 15. Brazil Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 16. Brazil Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 17. Brazil Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 18. Argentina Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 19. Argentina Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 20. Argentina Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 21. Rest of South America Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 22. Rest of South America Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 23. Rest of South America Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 24. Asia Pacific Eye Cancer Treatment, by Country USD Million (2016-2021)
  • Table 25. Asia Pacific Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 26. Asia Pacific Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 27. Asia Pacific Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 28. China Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 29. China Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 30. China Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 31. Japan Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 32. Japan Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 33. Japan Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 34. India Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 35. India Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 36. India Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 37. South Korea Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 38. South Korea Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 39. South Korea Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 40. Australia Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 41. Australia Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 42. Australia Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 43. Rest of Asia-Pacific Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 44. Rest of Asia-Pacific Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 45. Rest of Asia-Pacific Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 46. Europe Eye Cancer Treatment, by Country USD Million (2016-2021)
  • Table 47. Europe Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 48. Europe Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 49. Europe Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 50. Germany Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 51. Germany Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 52. Germany Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 53. France Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 54. France Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 55. France Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 56. Italy Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 57. Italy Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 58. Italy Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 59. United Kingdom Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 60. United Kingdom Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 61. United Kingdom Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 62. Netherlands Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 63. Netherlands Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 64. Netherlands Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 65. Rest of Europe Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 66. Rest of Europe Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 67. Rest of Europe Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 68. MEA Eye Cancer Treatment, by Country USD Million (2016-2021)
  • Table 69. MEA Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 70. MEA Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 71. MEA Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 72. Middle East Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 73. Middle East Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 74. Middle East Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 75. Africa Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 76. Africa Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 77. Africa Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 78. North America Eye Cancer Treatment, by Country USD Million (2016-2021)
  • Table 79. North America Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 80. North America Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 81. North America Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 82. United States Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 83. United States Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 84. United States Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 85. Canada Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 86. Canada Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 87. Canada Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 88. Mexico Eye Cancer Treatment, by Type USD Million (2016-2021)
  • Table 89. Mexico Eye Cancer Treatment, by Treatment USD Million (2016-2021)
  • Table 90. Mexico Eye Cancer Treatment, by End-User USD Million (2016-2021)
  • Table 91. Eye Cancer Treatment: by Type(USD/Units)
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Eye Cancer Treatment: by Type(USD Million)
  • Table 103. Eye Cancer Treatment Eyelid Tumor , by Region USD Million (2022-2027)
  • Table 104. Eye Cancer Treatment Corneal Tumor , by Region USD Million (2022-2027)
  • Table 105. Eye Cancer Treatment Uveal Melanoma , by Region USD Million (2022-2027)
  • Table 106. Eye Cancer Treatment Orbital Tumor , by Region USD Million (2022-2027)
  • Table 107. Eye Cancer Treatment: by End-User(USD Million)
  • Table 108. Eye Cancer Treatment Hospitals , by Region USD Million (2022-2027)
  • Table 109. Eye Cancer Treatment Clinics , by Region USD Million (2022-2027)
  • Table 110. Eye Cancer Treatment Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 111. Eye Cancer Treatment Others , by Region USD Million (2022-2027)
  • Table 112. South America Eye Cancer Treatment, by Country USD Million (2022-2027)
  • Table 113. South America Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 114. South America Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 115. South America Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 116. Brazil Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 117. Brazil Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 118. Brazil Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 119. Argentina Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 120. Argentina Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 121. Argentina Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 122. Rest of South America Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 123. Rest of South America Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 124. Rest of South America Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 125. Asia Pacific Eye Cancer Treatment, by Country USD Million (2022-2027)
  • Table 126. Asia Pacific Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 127. Asia Pacific Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 128. Asia Pacific Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 129. China Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 130. China Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 131. China Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 132. Japan Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 133. Japan Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 134. Japan Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 135. India Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 136. India Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 137. India Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 138. South Korea Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 139. South Korea Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 140. South Korea Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 141. Australia Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 142. Australia Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 143. Australia Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 144. Rest of Asia-Pacific Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 145. Rest of Asia-Pacific Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 146. Rest of Asia-Pacific Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 147. Europe Eye Cancer Treatment, by Country USD Million (2022-2027)
  • Table 148. Europe Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 149. Europe Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 150. Europe Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 151. Germany Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 152. Germany Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 153. Germany Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 154. France Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 155. France Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 156. France Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 157. Italy Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 158. Italy Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 159. Italy Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 160. United Kingdom Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 161. United Kingdom Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 162. United Kingdom Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 163. Netherlands Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 164. Netherlands Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 165. Netherlands Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 166. Rest of Europe Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 167. Rest of Europe Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 168. Rest of Europe Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 169. MEA Eye Cancer Treatment, by Country USD Million (2022-2027)
  • Table 170. MEA Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 171. MEA Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 172. MEA Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 173. Middle East Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 174. Middle East Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 175. Middle East Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 176. Africa Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 177. Africa Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 178. Africa Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 179. North America Eye Cancer Treatment, by Country USD Million (2022-2027)
  • Table 180. North America Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 181. North America Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 182. North America Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 183. United States Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 184. United States Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 185. United States Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 186. Canada Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 187. Canada Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 188. Canada Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 189. Mexico Eye Cancer Treatment, by Type USD Million (2022-2027)
  • Table 190. Mexico Eye Cancer Treatment, by Treatment USD Million (2022-2027)
  • Table 191. Mexico Eye Cancer Treatment, by End-User USD Million (2022-2027)
  • Table 192. Eye Cancer Treatment: by Type(USD/Units)
  • Table 193. Research Programs/Design for This Report
  • Table 194. Key Data Information from Secondary Sources
  • Table 195. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Eye Cancer Treatment: by Type USD Million (2016-2021)
  • Figure 5. Global Eye Cancer Treatment: by End-User USD Million (2016-2021)
  • Figure 6. South America Eye Cancer Treatment Share (%), by Country
  • Figure 7. Asia Pacific Eye Cancer Treatment Share (%), by Country
  • Figure 8. Europe Eye Cancer Treatment Share (%), by Country
  • Figure 9. MEA Eye Cancer Treatment Share (%), by Country
  • Figure 10. North America Eye Cancer Treatment Share (%), by Country
  • Figure 11. Global Eye Cancer Treatment: by Type USD/Units (2016-2021)
  • Figure 12. Global Eye Cancer Treatment share by Players 2021 (%)
  • Figure 13. Global Eye Cancer Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Eye Cancer Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 18. Spectrum Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Spectrum Pharmaceuticals Inc. (United States) Revenue: by Geography 2021
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2021
  • Figure 22. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 24. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 26. Takeda Pharmaceuticals Company Limited (India) Revenue, Net Income and Gross profit
  • Figure 27. Takeda Pharmaceuticals Company Limited (India) Revenue: by Geography 2021
  • Figure 28. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 30. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 32. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2021
  • Figure 34. Janssen Global Services, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 35. Janssen Global Services, LLC (United States) Revenue: by Geography 2021
  • Figure 36. Global Eye Cancer Treatment: by Type USD Million (2022-2027)
  • Figure 37. Global Eye Cancer Treatment: by End-User USD Million (2022-2027)
  • Figure 38. South America Eye Cancer Treatment Share (%), by Country
  • Figure 39. Asia Pacific Eye Cancer Treatment Share (%), by Country
  • Figure 40. Europe Eye Cancer Treatment Share (%), by Country
  • Figure 41. MEA Eye Cancer Treatment Share (%), by Country
  • Figure 42. North America Eye Cancer Treatment Share (%), by Country
  • Figure 43. Global Eye Cancer Treatment: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Novartis AG (Switzerland)
  • Spectrum Pharmaceuticals Inc. (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Bayer AG (Germany)
  • Amgen Inc. (United States)
  • Takeda Pharmaceuticals Company Limited (India)
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Janssen Global Services, LLC (United States)
Additional players considered in the study are as follows:
Sanofi (France) , AbbVie Inc. (United States) , Pfizer Inc. (United States) , Merck & Co. Inc. (United States) , Bristol-Myers Squibb Company (United States) , OncoMed Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation